β-Blockers in worsening heart failure: Good or bad?

European Heart Journal

Volumn 30, Issue 18, 2009, Pages 2177-2179

  Swedberg, Karl ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT;

CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; EVIDENCE BASED MEDICINE; HUMAN; NOTE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADRENERGIC BETA-ANTAGONISTS; DISEASE PROGRESSION; HEART FAILURE; HUMANS;

EID: 70349587661     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehp347     Document Type: Note

References (12)

1. Gaffney TE, Braunwald E. Importance of the adrenergic nervous system in the support of circulatory function in patients with congestive heart failure. Am J Med 1963;34:340-345.
2. Waagstein F, Hjalmarson A° , Varnauskas E, Wallentin I. Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy. Br Heart J 1975;37:1022-1036.
3. Swedberg K, Hjalmarson, Waagstein F, Wallentin I. Prolongation of survival in congestive cardiomyopathy during treatment with beta-receptor blockade. Lancet 1979;1:1374-1376. (Pubitemid 9204152)
4. Swedberg K, Hjalmarson, Waagstein F, Wallentin I. Beneficial effects of long-term beta-blockade in congestive cardiomyopathy. Br Heart J 1980;44:117-133. (Pubitemid 10000987)
5. McMurray J, Swedberg K. Treatment of chronic heart failure: a comparison between the major guidelines. Eur Heart J 2006;27:1773-1777.
6. Brophy JM, Joseph L, Rouleau JL. Beta-blockers in congestive heart failure. A Bayesian meta-analysis. Ann Intern Med 2001;134:550-560.
7. Swedberg K, Hjalmarson, Waagstein F, Wallentin I. Adverse effects of betablockade withdrawal in patients with congestive cardiomyopathy. Br Heart J 1980;44:134-142.
8. Fonarow GC, Abraham WT, Albert NM, Stough WG, Gheorghiade M, Greenberg BH, O'Connor CM, Sun JL, Yancy CW, Young JB. Influence of betablocker continuation or withdrawal on outcomes in patients hospitalized with heart failure: findings from the OPTIMIZE-HF program. J Am Coll Cardiol 2008; 52:190-199.
9. McMurray J, Cohen-Solal A, Dietz R, Eichhorn E, Erhardt L, Hobbs FD, Krum H, Maggioni A, McKelvie RS, Piña IL, Soler-Soler J, Swedberg K. Practical recommendations for the use of ACE inhibitors, beta-blockers, aldosterone antagonists and angiotensin receptor blockers in heart failure: putting guidelines into practice. Eur J Heart Fail 2005;7:710-721.
10. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA, Stromberg A, van Veldhuisen DJ, Atar D, Hoes AW, Keren A, Mebazaa A, Nieminen M, Priori SG, Swedberg K. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail 2008;10: 933-989.
11. Jondeau G, Neuder Y, Eicher J-C, Jourdain P, Fauveau E, Galinier M, Jegou A, Bauer F, Trochu JN, Bouzamondo A, Tanguy M-L, Lechat P, for the B-CONVINCED Investigators. B-CONVINCED: Beta-blocker CONtinuation Vs. INterruption in patients with Congestive heart failure hospitalizED for a decompensation episode. Eur Heart J 2009;30:2186-2192. doi:10.1093/eurheartj/ ehp323.
12. Metra M, Torp-Pedersen C, Cleland JG, Di Lenarda A, Komajda M, Remme WJ, Dei Cas L, Spark P, Swedberg K, Poole-Wilson PA. Should beta-blocker therapy be reduced or withdrawn after an episode of decompensated heart failure? Results from COMET. Eur J Heart Fail 2007;9:901-909.